Name: UMIN ID:
Unique ID issued by UMIN | UMIN000023761 |
---|---|
Receipt number | R000027377 |
Scientific Title | A phase I study of osimertinib with bevacizumab and randomized phase II study of osimertinib with or without bevacizumab in EGFR mutated, T790M positive patients who had progressed EGFR-TKIs. (WJOG8715L) |
Date of disclosure of the study information | 2016/08/25 |
Last modified on | 2021/08/31 10:14:03 |
No. | Disposal | Last modified on | Item of update | |
---|---|---|---|---|
1 | Insert | 2016/08/25 14:31:07 | ||
2 | Update | 2016/10/11 10:52:18 | Recruitment status Anticipated trial start date |
|
3 | Update | 2019/01/28 09:52:32 | Recruitment status |
|
4 | Update | 2019/08/28 09:50:22 | Date of IRB Last follow-up date |
|
5 | Update | 2019/08/28 09:50:53 | Number of participants that the trial has enrolled |
|
6 | Update | 2021/08/31 10:10:21 | 1st name of lead principal investigator Last name of lead principal investigator 1st name of lead principal investigator Last name of lead principal investigator Zip code Address Last name of contact person Last name of contact person Zip code Address Organization Organization Address Address Tel Secondary IDs Study ID_1 Org. issuing International ID_1 Org. issuing International ID_1 |
|
7 | Update | 2021/08/31 10:11:38 | Recruitment status |
|
8 | Update | 2021/08/31 10:14:03 | Publication of results URL related to results and publications |